Skip to main content

Table 1 Baseline characteristics of the cohort A

From: Empiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study

Characteristic Survivors (n = 289) Non-survivors (n = 47) p-value
Male gender (%) 77% 94% 0.009
Age (years) 53 (42, 63) 65 (56, 77) <0.001
Race (%)    0.66
Caucasian 64% 74%  
African American 15% 11%  
Hispanic 18% 13%  
Other 3% 2%  
Height (cm) 175.0 (165.1, 180.3) 175.0 (169.5, 183.0) 0.14
Weight (kg) 78.1 (65, 95.6) 80.0 (63.0, 99.0) 0.91
Serum Creatinine (mg/dl) 0.90 (0.7, 1.2) 1.10 (0.7, 1.5) 0.035
Creatinine Clearence (ml/min) 86.9 (61.0, 122) 64.0 (42.9, 86.3) <0.001
Pitt Bacteremia Score 1 (0, 3) 3 (2, 6) <0.001
Charlson Comorbidity Index 2 (1, 3) 2 (2, 4) 0.030
Guideline-recommended Vancomycin Dose Received (%) 33% 38% 0.48
Dose adjusted for renal function (%) 39% 59% 0.028
Vancomycin Started in Intensive Care Unit (%) 34% 83% <0.001
Initial Vancomycin Dose (mg/kg/day) 24.9 (19.6, 30.4) 21.0 (17.0, 29.0) 0.036
Nephrotoxins (%)    
Intravenous Contrast 34% 13% 0.004
Aminoglycosides 19% 19% 0.98
Vasopressors 7% 36% <0.001
Infection source (%)    <0.001
Bloodstream catheter-related 18% 36%  
Central nervous system 0.4% 0%  
Gastrointestinal 0.7% 0%  
Osteomyelitis 0.7% 4%  
Pulmonary 15% 36%  
Skin/muscle 36% 6%  
Other 20% 17%  
  1. A = Results are presented as median (interquartile range) unless otherwise noted.